Detalhe da pesquisa
1.
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Tumour Biol
; 46(s1): S177-S190, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545290
2.
A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
BMC Cancer
; 24(1): 379, 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38528478
3.
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Oncologist
; 28(4): e205-e211, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905578
4.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863955
5.
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Oncologist
; 25(10): 867-877, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32490560
6.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
7.
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
Cancer
; 125(14): 2394-2399, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30933354
8.
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Cancer
; 123(15): 2936-2944, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472537
9.
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
Oncologist
; 22(1): 3-11, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27821794
10.
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 17(5): 642-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27080216
11.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26708155
12.
Atezolizumab Treatment of Nonsquamous NSCLC.
N Engl J Med
; 379(12): 1188, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30231231
13.
Best Practices in Treatment Selection for Patients With Advanced NSCLC.
Cancer Control
; 23(4 Suppl): 2-14, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27842052
14.
HSP90 inhibitors in lung cancer: promise still unfulfilled.
Clin Adv Hematol Oncol
; 14(5): 346-56, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27379696
15.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 16(7): 763-74, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26045340
16.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
17.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Cancer
; 121(3): 448-56, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273224
18.
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
Oncologist
; 20(2): 105-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616430
19.
The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Curr Oncol Rep
; 17(6): 26, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25947099
20.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(1): 59-68, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24331154